Christine Bangert, Katharina Rindler, Thomas Krausgruber, Natalia Alkon, Felix M Thaler, Harald Kurz, Tanya Ayub, Denis Demirtas, Nikolaus Fortelny, Vera Vorstandlechner, Wolfgang M Bauer, Tamara Quint, Michael Mildner, Constanze Jonak, Adelheid Elbe-Bürger, Johannes Griss, Christoph Bock, Patrick M Brunner
Therapeutic options for autoimmune diseases typically consist of broad and targeted immunosuppressive agents. However, sustained clinical benefit is rarely achieved, as the disease phenotype usually returns after cessation of treatment. To better understand tissue-resident immune memory in human disease, we investigated patients with atopic dermatitis (AD) who underwent short-term or long-term treatment with the IL-4Rα blocker dupilumab. Using multi-omics profiling with single-cell RNA sequencing and multiplex proteomics, we found significant decreases in overall skin immune cell counts and normalization of transcriptomic dysregulation in keratinocytes consistent with clearance of disease...
January 22, 2021: Science Immunology